search

TriSalus Life Sciences Inc. (TLSI)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
FDA Clears TriNav Advance for Expanded Liver Embolization Access
Sep 25, 2026

FDA Clears TriNav Advance for Expanded Liver Embolization Access

The FDA has granted 510(k) clearance to TriSalus Life Sciences for its TriNav Advance device, designed to enhance tumor penetration during liver embolization procedures. This catheter-based system extends the company's Pressure-Enabled Drug Delivery (PEDD) technology to smaller hepatic vessels, utilizing a SmartValve mechanism to improve drug and microsphere delivery to tumors while minimizing exposure to healthy tissue. Preclinical studies have supported the effectiveness of PEDD in increasing therapeutic concentration within tumors.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance
Sep 23, 2026

TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance

TriSalus Life Sciences (NASDAQ:TLSI) shares rose 15.6% in pre-market trading after receiving 510(k) clearance from the FDA for its TriNav Advance device. This new device is designed to enhance pressure-enabled drug delivery in liver embolization procedures, particularly for smaller, distal vessels. TriSalus plans a limited market release in the coming weeks and previously raised its full-year 2026 revenue guidance.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish